menu
    • menu
    [{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"6","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Lesieur","sponsor":"Institut National De La Recherche Agronomique | Centre de Recherche en Nutrition Humaine d'Auvergne","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Lesieur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oil","sponsorNew":"Lesieur \/ Institut National De La Recherche Agronomique | Centre de Recherche en Nutrition Humaine d'Auvergne","highestDevelopmentStatusID":"1","companyTruncated":"Lesieur \/ Institut National De La Recherche Agronomique | Centre de Recherche en Nutrition Humaine d'Auvergne"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Lumenis | Mucosa Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Lumenis | Mucosa Innovations","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Lumenis | Mucosa Innovations"},{"orgOrder":0,"company":"Spanish National Research Council","sponsor":"Andalusian Health Service | Universidad Pablo de Olavide","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Endocrinology","graph2":"Phase II","graph3":"Spanish National Research Council","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish National Research Council \/ Andalusian Health Service | Universidad Pablo de Olavide","highestDevelopmentStatusID":"8","companyTruncated":"Spanish National Research Council \/ Andalusian Health Service | Universidad Pablo de Olavide"},{"orgOrder":0,"company":"Northumbria University","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ BASF"},{"orgOrder":0,"company":"Mucosa innovations","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Mucosa innovations","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mucosa innovations \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mucosa innovations \/ Undisclosed"},{"orgOrder":0,"company":"Cesa Projects","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cesa Projects","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cesa Projects \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cesa Projects \/ Undisclosed"},{"orgOrder":0,"company":"Mucosa innovations","sponsor":"Universidad de Granada","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Mucosa innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mucosa innovations \/ Universidad de Granada","highestDevelopmentStatusID":"9","companyTruncated":"Mucosa innovations \/ Universidad de Granada"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Olive

    Menu

    Olive

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Baxter Healthcare Corporation

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Baxter Secures FDA Approval for Clinolipid in Neonates and Pediatrics

                            Details : Clinolipid is a mixed oil lipid emulsion providing essential fatty acids and calories in parenteral nutrition when oral or enteral nutrition isn’t viable.

                            Product Name : Clinolipid

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 13, 2024

                            Lead Product(s) : Olive

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spanish National Research Council

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            Spanish National Research Council

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Andalusian Health Service | Universidad Pablo de Olavide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 11, 2023

                            Lead Product(s) : Olive

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Andalusian Health Service | Universidad Pablo de Olavide

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mucosa innovations

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mucosa innovations

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Stomatitis.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 02, 2022

                            Lead Product(s) : Olive

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Instituto de Investigacion Sanitaria La Fe

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            Instituto de Investigacion Sanitaria La Fe

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Lumenis | Mucosa Innovations

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Female Urogenital Diseases.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            October 18, 2022

                            Lead Product(s) : Olive

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Lumenis | Mucosa Innovations

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mucosa innovations

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mucosa innovations

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II/ Phase III

                            Sponsor : Universidad de Granada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral...

                            Details : Olive is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 19, 2022

                            Lead Product(s) : Olive

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Universidad de Granada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The First Affiliated Hospital with Nanjing Medical University

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            The First Affiliated Hospital with Nanjing Medical University

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safely and Efficacy of ClinOleic-based Lipid Parenteral Nutrition

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Nutritional Supplement Toxicity.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 09, 2019

                            Lead Product(s) : Olive

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Northumbria University

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            Northumbria University

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : BASF

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Memory Consolidation in Healthy Adults

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 19, 2018

                            Lead Product(s) : Olive

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : BASF

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lesieur

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            Lesieur

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Institut National De La Recherche Agronomique | Centre de Recherche en Nutrition Humaine d'Auvergne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Olive Oil Polyphenols, Vitamin D, Docosahexaenoic Acid (DHA) and Locomotor Function (PolivD3)

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Bone Diseases, Metabolic.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 11, 2013

                            Lead Product(s) : Olive

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Institut National De La Recherche Agronomique | Centre de Recherche en Nutrition Humaine d'Auvergne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cesa Projects

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Cesa Projects

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olive

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

                            Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 01, 2012

                            Lead Product(s) : Olive

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth